CN104271590B - 用于癌治疗的肽剂 - Google Patents

用于癌治疗的肽剂 Download PDF

Info

Publication number
CN104271590B
CN104271590B CN201380016372.7A CN201380016372A CN104271590B CN 104271590 B CN104271590 B CN 104271590B CN 201380016372 A CN201380016372 A CN 201380016372A CN 104271590 B CN104271590 B CN 104271590B
Authority
CN
China
Prior art keywords
peptide
cell
amino acid
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380016372.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104271590A (zh
Inventor
M.V.阿格雷兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InterK Peptide Therapeutics Ltd
Original Assignee
Inter K Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012900259A external-priority patent/AU2012900259A0/en
Application filed by Inter K Pty Ltd filed Critical Inter K Pty Ltd
Publication of CN104271590A publication Critical patent/CN104271590A/zh
Application granted granted Critical
Publication of CN104271590B publication Critical patent/CN104271590B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380016372.7A 2012-01-24 2013-01-24 用于癌治疗的肽剂 Active CN104271590B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2012900259A AU2012900259A0 (en) 2012-01-24 Agents for use in cancer therapy
AU2012900259 2012-01-24
AU2012904368 2012-10-06
AU2012904368A AU2012904368A0 (en) 2012-10-06 Anti-cancer peptides
PCT/AU2013/000045 WO2013110120A1 (en) 2012-01-24 2013-01-24 Peptide agents for cancer therapy

Publications (2)

Publication Number Publication Date
CN104271590A CN104271590A (zh) 2015-01-07
CN104271590B true CN104271590B (zh) 2018-06-05

Family

ID=48872819

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380016372.7A Active CN104271590B (zh) 2012-01-24 2013-01-24 用于癌治疗的肽剂

Country Status (7)

Country Link
US (1) US9403877B2 (https=)
EP (1) EP2807180B1 (https=)
JP (1) JP6249447B2 (https=)
CN (1) CN104271590B (https=)
AU (1) AU2013202137B2 (https=)
CA (1) CA2862485C (https=)
WO (1) WO2013110120A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101644982B1 (ko) * 2015-07-23 2016-08-02 주식회사 엔솔바이오사이언스 신규 펩타이드 및 그 용도
CN105294839A (zh) * 2015-10-28 2016-02-03 上海大学 对新生血管形成有阻断功能的多肽化合物及其应用
CN106146620A (zh) * 2016-07-09 2016-11-23 青岛大学 具有抑制癌细胞生长活性的肽及其应用
CN105936642A (zh) * 2016-07-09 2016-09-14 青岛大学 具有抑制癌细胞生长活性的肽及其应用
CN106167513A (zh) * 2016-07-09 2016-11-30 青岛大学 具有抑制癌细胞生长活性的肽及其应用
CN106084012A (zh) * 2016-07-09 2016-11-09 青岛大学 具有抑制癌细胞生长活性的肽及其应用
CN105936643A (zh) * 2016-07-09 2016-09-14 青岛大学 具有抑制癌细胞生长活性的肽及其应用
GB201706472D0 (en) * 2017-04-24 2017-06-07 Cancer Res Tech Ltd Tumour-targeting peptide variants
CN111094324B (zh) * 2018-03-14 2023-10-10 武汉博威德生物技术有限公司 一种溶瘤病毒、合成dna序列及其应用
JP7386852B2 (ja) * 2018-05-15 2023-11-27 インテルク ペプチド セラピューティクス リミテッド ペプチド活性化剤
JP7644000B2 (ja) * 2018-05-15 2025-03-11 インテルク ペプチド セラピューティクス リミテッド 活性化剤
CN113166205A (zh) * 2018-11-30 2021-07-23 英特肽治疗有限公司 用于改善皮肤病状的多肽和方法
CN110893236A (zh) * 2019-10-09 2020-03-20 中山大学 溶酶体靶向的抗体药物偶联物及其应用
CN112646018B (zh) * 2021-01-25 2023-04-28 井冈山大学 一种抑制肿瘤细胞增殖和转移的生物活性肽及其应用
KR20240044517A (ko) * 2021-08-20 2024-04-04 인터크 펩타이드 테라퓨틱스 리미티드 암 및 암 요법과 연관된 자가면역을 포함한 자가면역을 치료하기 위한 조성물 및 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037308A1 (en) * 2003-10-17 2005-04-28 Inter-K Pty Limited Methods and agents for the treatment of cancer
WO2010094085A1 (en) * 2009-02-23 2010-08-26 Inter-K Pty Limited Inhibition of multiple cell activation pathways

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162956A1 (en) 1997-04-07 2003-08-28 Human Genome Sciences, Inc. Leukocyte regulatory factors 1 and 2
ATE385503T1 (de) * 1999-06-28 2008-02-15 Inter K Pty Ltd Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien
AU2001275423B2 (en) * 2000-06-09 2007-01-11 Regulon, Inc. Encapsulation of polynucleotides and drugs into targeted liposomes
US6696546B1 (en) * 2000-11-06 2004-02-24 The Trustees Of Columbia University In The City Of New York Peptide that kills growing but not stationary cells
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
WO2002053726A2 (en) * 2001-01-02 2002-07-11 Hybrigenics Protein-protein interactions in adipocyte cells
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
JP4458846B2 (ja) 2001-10-15 2010-04-28 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド ｉｎｖｉｔｒｏおよびｉｎｖｉｖｏにおけるＤＮＡ導入および遺伝子療法のためのベクターとしての完全なミニ細胞
EP1451578B1 (en) * 2001-11-16 2013-08-21 Genentech, Inc. Use of angptl3 antagonists for the treatment of liver diseases
WO2005009346A2 (en) 2003-06-24 2005-02-03 Mirus Corporation Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
WO2005105837A2 (en) * 2004-04-14 2005-11-10 Brigham And Women's Hospital, Inc. Use of the ribosomal protein rpl41 to treat infections and inhibit cancer
WO2006029005A2 (en) 2004-09-02 2006-03-16 Oklahoma Medical Research Foundation Promoter substitution for immunoglobulin therapy
WO2006029981A1 (en) 2004-09-13 2006-03-23 Vib Vzw Abin-mediated protection against lung inflammatory disease
PT2229956E (pt) 2004-09-13 2013-07-31 Genzyme Corp Contruções multiméricas
WO2006031996A2 (en) 2004-09-14 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeting viruses using a modified sindbis glycoprotein
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
US7912214B2 (en) 2007-07-20 2011-03-22 Amadeus S.A.S. Method and system for generating and controlling the distribution and use of personal promotion codes by targeted customers
US20110105408A1 (en) * 2008-02-22 2011-05-05 Inter-K Pty Limited Therapeutic peptides
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
WO2010039778A2 (en) 2008-09-30 2010-04-08 Zirus, Inc. Mammalian genes involved in infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037308A1 (en) * 2003-10-17 2005-04-28 Inter-K Pty Limited Methods and agents for the treatment of cancer
WO2010094085A1 (en) * 2009-02-23 2010-08-26 Inter-K Pty Limited Inhibition of multiple cell activation pathways

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Novel Anti-Cancer Peptides Comprising Three Amino Acids;Agrez M.等;《Journal of Cancer Therapy》;20120831;第3卷(第4期);第230-236页 *

Also Published As

Publication number Publication date
JP6249447B2 (ja) 2017-12-20
CA2862485A1 (en) 2013-08-01
JP2015510393A (ja) 2015-04-09
US9403877B2 (en) 2016-08-02
CA2862485C (en) 2021-05-11
EP2807180A1 (en) 2014-12-03
CN104271590A (zh) 2015-01-07
AU2013202137B2 (en) 2015-09-10
WO2013110120A1 (en) 2013-08-01
EP2807180A4 (en) 2016-01-06
US20150110744A1 (en) 2015-04-23
EP2807180B1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
CN104271590B (zh) 用于癌治疗的肽剂
JP7007423B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP7041187B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
AU2013202137A1 (en) Peptide agents for cancer therapy
TWI598441B (zh) 穿膜胜肽以及包含該胜肽之共軛物及組成物（四）
JP7312948B2 (ja) Ａｔｆ５ペプチド多様体及びそれらの使用
CN104130315A (zh) 一种特异靶向her2蛋白的多肽
US8653236B2 (en) Therapeutic agents
WO2018152446A2 (en) Cell-penetrating atf5 polypeptides and uses thereof
EP4520767A1 (en) Peptide kinase inhibitors and methods of use thereof
EP3582800A1 (en) Peptide kinase inhibitors and methods of use thereof
AU2009270340A1 (en) Therapeutic agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant